What is the 13F Pro Quality Score for MNPR?

13F Pro ranks Monopar Therapeutics (MNPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MNPR's current score at https://13fpro.ai/research/MNPR (free sign-up required for the full ranking).

Where does 13F Pro source MNPR data?

All Monopar Therapeutics fundamentals and ownership data come directly from SEC EDGAR. Monopar Therapeutics files with the SEC under CIK 1645469. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MNPR in?

Monopar Therapeutics (MNPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MNPR research updated on 13F Pro?

MNPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Monopar Therapeutics(MNPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1645469 MNPR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MNPR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Monopar Therapeutics (MNPR), a Healthcare sector company. MNPR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Monopar Therapeutics reports net income of $-3.9M, free cash flow of $-3.5M. Top institutional holders of MNPR by reported 13-F value include JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., Saturn V Capital Management, based on the most recent SEC filings. MNPR trades on the Nasdaq exchange and files with the SEC under CIK 1645469. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monopar Therapeutics directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-3.9M

Free Cash Flow

Q1 2026

$-3.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY20 —FY23 $0.00FY24 $0.00FY25 $0.00

Net Income

+12.0% YoY

$-13.7MFY 2025

FY20 $-6.3MFY23 $-8.4MFY24 $-15.6MFY25 $-13.7M

Operating Income

-3.4% YoY

$-16.7MFY 2025

FY20 $-6.5MFY23 $-8.8MFY24 $-16.2MFY25 $-16.7M

Total Assets

+133.4% YoY

$140.7MFY 2025

FY20 $16.9MFY23 $7.3MFY24 $60.3MFY25 $140.7M

Op. Cash Flow

-90.5% YoY

$-12.2MFY 2025

FY20 $-4.7MFY23 $-7.9MFY24 $-6.4MFY25 $-12.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2016
Revenue	$0.00	$0.00	$0.00	—	$0.00	$0.00
Net Income	$-13.7M +12.0%	$-15.6M -85.5%	$-8.4M -33.3%	$-6.3M -49.2%	$-4.2M -256.3%	$-1.2M
Operating Income	$-16.7M -3.4%	$-16.2M -83.0%	$-8.8M -35.7%	$-6.5M -50.5%	$-4.3M -262.5%	$-1.2M
Total Assets	$140.7M +133.4%	$60.3M +720.8%	$7.3M -56.5%	$16.9M +26.3%	$13.4M +361.1%	$2.9M
Operating Cash Flow	$-12.2M -90.5%	$-6.4M +18.5%	$-7.9M -68.6%	$-4.7M -54.5%	$-3.0M -152.6%	$-1.2M

AI Insight: MNPR Financial Trends

Monopar remains pre-revenue with accelerating operating losses and cash burn despite equity raise in Q3 2025.

• Operating income deteriorated from $-2M in Q2 2024 to $-5M in Q1 2026, reflecting intensifying cash burn.

• Equity surged from $5M–$6M range (Q2–Q3 2024) to $135M–$142M (Q3 2025–Q1 2026), consistent with capital raise.

• Operating cash outflow averaged $-2.5M per quarter in latest four quarters; no revenue generation yet.

⚠ Equity declined $7M from Q3 2025 peak ($142M) through Q1 2026 ($135M), signaling ongoing burn without revenue offset.

⚠ Net losses consistently negative; Q4 2025 loss of $-5M marks worst quarter since capital raise.

AI Insight: MNPR Ratio Trends

Monopar's return metrics have improved sharply from Q2 2024 lows but remain deeply negative, suggesting the company is still burning capital despite trajectory improvement.

• ROE improved from -112.7% in Q2 2024 to -11.5% in Q1 2026, a 101pp swing. ROA and ROIC show similar recovery across the period.

• Q3 2025 marked the best quarter in the dataset: ROE -9.7%, ROA -9.5%, ROIC -11.6%; slight deterioration in Q4 2025 and Q1 2026.

⚠ All returns remain negative. Company has not achieved profitability or positive capital productivity in any quarter shown.

⚠ Sequential deterioration from Q3 2025 to Q1 2026 despite overall 12-month improvement trend. Investigate Q4 2025 and Q1 2026 drivers.

Get alerted when MNPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Monopar Therapeutics including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MNPR

JANUS HENDERSON GROUP PLC
$72.1M1,317,410 sh
RA CAPITAL MANAGEMENT, L.P.
$36.6M667,207 sh
Saturn V Capital Management LP
$18.9M345,626 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$17.7M323,745 sh
BlackRock, Inc.
$17.3M316,567 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$16.9M309,195 sh
Siren, L.L.C.
$14.8M270,118 sh
ADAR1 Capital Management, LLC
$14.5M264,278 sh
Polar Capital Holdings Plc
$12.4M226,526 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.0M218,463 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$72.1M	1,317,410
RA CAPITAL MANAGEMENT, L.P.	$36.6M	667,207
Saturn V Capital Management LP	$18.9M	345,626
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$17.7M	323,745
BlackRock, Inc.	$17.3M	316,567
ADAGE CAPITAL PARTNERS GP, L.L.C.	$16.9M	309,195
Siren, L.L.C.	$14.8M	270,118
ADAR1 Capital Management, LLC	$14.5M	264,278
Polar Capital Holdings Plc	$12.4M	226,526
VANGUARD CAPITAL MANAGEMENT LLC	$12.0M	218,463

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MNPR on your watchlist

Track score changes the day Monopar Therapeutics files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MNPR a good stock to buy?

13F Pro's AI-powered analysis of Monopar Therapeutics (MNPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNPR are available on the MNPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MNPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Monopar Therapeutics's investment landscape.